Biohaven epilepsy drug hit by partial FDA hold
FDA issues a partial clinical hold on Biohaven’s BHV-7000 enrollment, while existing dosing and 2026 topline timelines continue and a global Kv7 licensing deal advances.
Rhea-AI Filing Summary
Biohaven Ltd. (BHVN) reports that the U.S. FDA issued a partial clinical hold on the BHV-7000 epilepsy program on September 4, 2026, pausing new patient enrollment while additional nonclinical studies further characterize a specific rodent metabolite.
Dosing continues for more than 600 already randomized patients across the BHV-7000 program, including BHV7000-303, which is fully enrolled, with topline data still expected in the second half of 2026. Over 1,200 participants have received BHV-7000 to date, and the safety profile has generally been described as safe and well-tolerated. BHV7000-302 and the open-label extension study will keep dosing but will not enroll new patients until the additional nonclinical data are available.
Separately, on August 26, 2026, Biohaven’s subsidiary Biohaven Bioscience Ireland Limited entered into a License Agreement under which SK Biopharmaceuticals will receive an exclusive, royalty-bearing, worldwide license to Biohaven’s Kv7 ion channel platform, including BHV-7000, subject to closing conditions including Hart-Scott-Rodino review. All clinical and nonclinical data, including metabolite characterization, were disclosed to SK Biopharmaceuticals before signing.
Positive
- SK Biopharmaceuticals obtains an exclusive, worldwide, royalty-bearing license to Biohaven’s Kv7 ion channel platform, including BHV-7000, creating a strategic partnership around this asset.
Negative
- The FDA imposed a partial clinical hold on BHV-7000 on September 4, 2026, pausing new patient enrollment across the program pending additional nonclinical metabolite data.
- Enrollment in the pivotal BHV7000-302 trial for refractory focal epilepsy is paused for new patients until further nonclinical data on the metabolite are available.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Participants dosed with BHV-7000: Over 1,200 participants
Randomized patients currently dosed: More than 600 patients
Global clinical sites selected: More than 110 sites
+5 more
8 metrics
Participants dosed with BHV-7000
Over 1,200 participants
Cumulative across the BHV-7000 development program
Randomized patients currently dosed
More than 600 patients
Already randomized in the BHV-7000 program at time of partial hold
Global clinical sites selected
More than 110 sites
Selected for the first of two focal epilepsy trials BHV7000-302 and BHV7000-303
Trial durations
8-week and 12-week trials
Randomized, double-blind, placebo-controlled pivotal BHV-7000 studies
End-of-Phase 2 meeting timing
January 2024
Meeting with FDA to advance BHV-7000 to Phase 3 trials
Partial clinical hold date
September 4, 2026
Date FDA issued partial clinical hold pausing new enrollment
License Agreement date
August 26, 2026
Date Biohaven’s subsidiary entered License Agreement with SK Biopharmaceuticals
Topline readout target
Second half of 2026
Target timing for BHV7000-303 topline data
Key Terms
partial clinical hold, open-label extension, Hart-Scott-Rodino, royalty-bearing, +2 more
6 terms
partial clinical hold regulatory
"FDA instructed the Company to pause new enrollment and issued a partial clinical hold"
A partial clinical hold is a temporary restriction imposed by health regulators that pauses certain parts of a medical trial while allowing others to continue. For investors, it signals potential delays or issues with a company's development of new treatments, which can impact future growth prospects. It’s like putting a project on hold in some areas while others keep moving forward.
open-label extension medical
"BHV7000-201 is the associated open-label extension (“OLE”) study"
An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.
Hart-Scott-Rodino regulatory
"completion of the required Hart-Scott-Rodino (“HSR”) submission required for closing"
The Hart-Scott-Rodino Antitrust Act is a U.S. law that requires companies to notify federal regulators and wait for a review before closing large mergers or acquisitions. Think of it as a required heads-up and cooling-off period so antitrust officials can check whether a deal would unfairly reduce competition; for investors this can delay or block transactions and change the risk, timing, and expected value of corporate deals.
royalty-bearing financial
"SKBP will have an exclusive, royalty-bearing, worldwide license"
An asset, contract, or revenue stream described as royalty-bearing requires regular payments calculated as a percentage or fixed fee based on sales, production, or use. For investors, this matters because such payments either reduce the cash an owner keeps from a product or create a predictable income stream for the party receiving the royalty—think of it like renting out a patent or mine where the operator pays the owner a portion of what they earn.
Kv7 ion channel platform medical
"exclusive, royalty-bearing, worldwide license to Biohaven’s Kv7 ion channel platform"
refractory focal epilepsy medical
"two pivotal studies evaluating the efficacy of BHV-7000 in refractory focal epilepsy"
FAQ
What FDA action did Biohaven (BHVN) disclose regarding BHV-7000?
The FDA issued a partial clinical hold on September 4, 2026, pausing new patient enrollment in the BHV-7000 program due to insufficient nonclinical information about a specific rodent metabolite’s potential risk to humans.
Are BHV-7000 patients still being dosed despite the partial hold on BHVN?
Yes. Dosing continues for all patients already randomized in the BHV-7000 program, including more than 600 patients and the fully enrolled BHV7000-303 trial. The hold applies only to new enrollment.
How does the FDA hold affect the BHV7000-303 trial timelines for BHVN?
Biohaven states there is no impact on BHV7000-303 timelines because enrollment and randomization were already completed. Dosing continues and topline data remain expected in the second half of 2026.
What is happening with the BHV7000-302 trial in Biohaven’s program?
BHV7000-302 will continue dosing existing patients, but new enrollment is paused while additional nonclinical studies clarify the significance of the metabolite findings. The open-label extension study also continues dosing.
What licensing deal did Biohaven (BHVN) sign with SK Biopharmaceuticals?
On August 26, 2026, Biohaven’s subsidiary agreed to grant SK Biopharmaceuticals an exclusive, royalty-bearing, worldwide license to its Kv7 ion channel platform, including BHV-7000, subject to closing conditions such as Hart-Scott-Rodino review.
How many participants have been exposed to BHV-7000 so far?
Biohaven reports that over 1,200 participants have been dosed with BHV-7000 across the development program, and the clinical safety profile has generally been described as safe and well-tolerated to date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
